Abstract
Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell lymphomas (DLBCLs) confined to the central nervous system (CNS). Despite extensive research, the molecular alterations leading to PCNSL have not been fully elucidated. In order to provide a comprehensive description of the genomic and transcriptional landscape of PCNSL, we here performed whole-genome and transcriptome sequencing and integrative analysis of 51 lymphomas presenting in the CNS, including 42 EBV-negative PCNSL, 6 secondary CNS lymphomas (SCNSL) and 3 EBV+ CNSL and matched controls. The results were compared to an independent validation cohort of 31 FFPE CNSL specimens (PCNSL, n = 19; SCNSL, n = 9; EBV+ CNSL, n = 3) as well as 39 FL and 36 systemic DLBCL cases outside the CNS. Somatic genomic alterations in PCNSL mainly affect the JAK-STAT, NFkB, and B-cell receptor signaling pathways, with hallmark recurrent mutations including MYD88 L265P (67%) and CD79B (63%), CDKN2A deletions (83%) and also non-coding RNA genes such as MALAT1 (70%), NEAT (60%), and MIR142 (80%). Kataegis events, which affected 15 of 50 identified driver genes and 21 of the top 50 mutated ncRNAs, played a decisive role in shaping the mutational repertoire of PCNSL. Compared to systemic DLBCL, PCNSLs exhibited significantly more focal deletions in 6p21 targeting the HLA-D locus that encodes for MHC class II molecules as a potential mechanism of immune evasion. Mutational signatures correlating with DNA replication and mitosis (SBS1, ID1 and ID2) were significantly enriched in PCNSL (SBS1: p = 0.0027, ID1/ID2: p < 1×10−4). Furthermore, TERT gene expression was significantly higher in PCNSL compared to ABC-DLBCL (p = 0.027). Although PCNSL share many genetic alterations with systemic ABC-DLBCL in the same signaling pathways, transcriptome analysis clearly distinguished both into distinct molecular subtypes. EBV+ CNSL cases may be distinguished by lack of recurrent mutational hotspots apart from IG and HLA-DRB loci.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JR is a participant in the BIH-Charite Clinical Scientist Program funded by the Charite-Universitaetsmedizin Berlin and the Berlin Institute of Health. CL is supported by postdoctoral Beatriu de Pinos from Secretaria d Universitats I Recerca del Departament d Empresa i Coneixement de la Generalitat de Catalunya and by Marie Sklodowska-Curie COFUND program from H2020 (2018-BP-00055). The research reported in the article was financially supported by the German Cancer Consortium (DKTK) and the Heidelberg Center for Personalized Oncology (DKFZ-HIPO).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Charite ethics committee (Chariteplatz 1, 10117 Berlin, Germany) approved the study (EA1/245/13).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
The raw sequencing data of the 51 CNSL samples has been deposited at the European Genome-Phenome Archive under the accession number EGAS00001005339. Accession to the ICGC MMML-Seq data is available via the data accession committee of the ICGC (see: www.ICGC.org, Huebschmann et al). All somatic mutation calls and integrated mutations tables on which the analysis was performed can be downloaded from Zenodo (https://doi.org/10.5281/zenodo.5106351)
Abbreviations
- CNSL
- Central nervous system lymphoma
- PCNSL
- Primary central nervous system lymphoma
- SCNSL
- Secondary central nervous system lymphoma
- ABC
- Activated B-cell like
- GCB
- Germinal center B-cell like
- WGS
- Whole-genome sequencing
- RNAseq
- RNA sequencing
- H&E
- Hematoxylin and eosin
- DLBCL
- Diffuse large B-cell lymphoma
- FL
- Follicular lymphoma
- MYD88
- Myeloid differentiation primary response 88
- NFkB
- Nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells
- RT-PCR
- Real-time PCR
- SV direct
- Structural variant with breakpoint in the gene body
- cnLOH
- Copy number neutral loss of heterozygosity
- CNA
- Copy number aberration
- aSHM
- Aberrant somatic hyper-mutation
- SNV
- Single nucleotide variant
- indel
- Small insertion or deletion
- EBV
- Epstein-Barr virus
- FF
- Fresh-frozen
- FFPE
- Formalin-fixed and paraffin-embedded
- VAF
- Variant allele frequency
- AID
- Activation induced deaminase
- lncRNA
- Long non-coding RNAs
